Published in Drug Metab Dispos on December 17, 2004
The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31
Do you know the sex of your cells? Am J Physiol Cell Physiol (2013) 1.49
Gender-specific differences in expression in human lymphoblastoid cell lines. Pharmacogenet Genomics (2007) 1.18
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biol (2009) 0.99
Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther (2010) 0.90
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol (2012) 0.88
Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol (2012) 0.82
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. Eur J Clin Pharmacol (2008) 0.77
Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. Br J Clin Pharmacol (2006) 0.75
No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. PLoS One (2015) 0.75
Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes. Medicine (Baltimore) (2015) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev (2003) 5.91
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell (2008) 5.34
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Bioequivalence approaches for highly variable drugs and drug products. Pharm Res (2007) 2.36
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. Pediatr Dermatol (2012) 2.00
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci (2002) 1.84
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr (2007) 1.76
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics (2008) 1.72
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68
Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci (2011) 1.67
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 1.52
Cigarette smoking, stress-induced analgesia and pain perception in men and women. Pain (2005) 1.47
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
SARS in hospital emergency room. Emerg Infect Dis (2004) 1.44
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Effect of a vascular endothelial cadherin antagonist in a rat lung transplant model. Ann Thorac Surg (2013) 1.43
Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb (2014) 1.40
Equivalence approaches. Clin Pharmacol Ther (2002) 1.38
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol (2005) 1.33
Complete genome sequence of Lactococcus lactis subsp. lactis CV56, a probiotic strain isolated from the vaginas of healthy women. J Bacteriol (2011) 1.31
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30
Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes (2007) 1.29
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos (2002) 1.26
Longitudinal analysis of chlorhexidine susceptibilities of nosocomial methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan. J Antimicrob Chemother (2008) 1.24
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J (2012) 1.22
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology (2004) 1.21
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med (2008) 1.20
Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol Cell Biol (2009) 1.19
Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis (2002) 1.19
Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol (2010) 1.18
The Environmental Polymorphisms Registry: a DNA resource to study genetic susceptibility loci. Hum Genet (2008) 1.18
Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. J Neuroimmunol (2010) 1.17
Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci (2010) 1.14
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet (2010) 1.12
A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr (2006) 1.12
Evoked response of heart rate variability using short-duration white noise. Auton Neurosci (2010) 1.11
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm (2006) 1.11
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab (2002) 1.10
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol (2009) 1.10
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Comparison of an automated repetitive-sequence-based PCR microbial typing system with pulsed-field gel electrophoresis for molecular typing of vancomycin-resistant Enterococcus faecium. J Clin Microbiol (2010) 1.09
Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system. Am J Public Health (2009) 1.09
Hospice utilization in Taiwan by cancer patients who died between 2000 and 2004. J Pain Symptom Manage (2007) 1.09
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. J Aerosol Med Pulm Drug Deliv (2010) 1.08
Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (2010) 1.08
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
Growth failure in early life: an important manifestation of Turner syndrome. Horm Res (2002) 1.06
A method for fitting regression splines with varying polynomial order in the linear mixed model. Stat Med (2006) 1.05
An evaluation of HIV testing among inmates in the North Carolina prison system. Am J Public Health (2009) 1.05
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol (2009) 1.05
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos (2012) 1.04
Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage (2008) 1.04
Xanthogranulomatous pyelonephritis successfully treated with antibiotics only. J Chin Med Assoc (2008) 1.04
Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol (2007) 1.03
Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited. J Gastroenterol Hepatol (2011) 1.03
Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology (2010) 1.03
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci (2012) 1.02
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol (2012) 1.01
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr (2007) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis (2002) 1.00
Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res (2002) 0.99
Prediction of lung function response for populations exposed to a wide range of ozone conditions. Inhal Toxicol (2012) 0.98
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther (2005) 0.98
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Discrimination between postinfectious IgA-dominant glomerulonephritis and idiopathic IgA nephropathy. Ren Fail (2010) 0.97
Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos (2004) 0.97
Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv (2011) 0.97
Ozone exposure-response model for lung function changes: an alternate variability structure. Inhal Toxicol (2013) 0.97
Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol (2003) 0.96
Effects of a prolonged standardized diet on normalizing the human metabolome. Am J Clin Nutr (2009) 0.96
Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology (2010) 0.95
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm (2009) 0.94
Perceived uncertainty, social support and psychological adjustment in older patients with cancer being treated with surgery. J Clin Nurs (2009) 0.94